{"id":730116,"date":"2025-02-04T09:40:01","date_gmt":"2025-02-04T09:40:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=730116"},"modified":"2025-02-04T09:40:01","modified_gmt":"2025-02-04T09:40:01","slug":"peraso-inc-nasdaq-prso-rides-military-ai-boom-as-defense-spending-surges-more-stocks-inside","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/peraso-inc-nasdaq-prso-rides-military-ai-boom-as-defense-spending-surges-more-stocks-inside_730116.html","title":{"rendered":"Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges &#8211; More Stocks Inside"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/02\/1738675182.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges - More Stocks Inside\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/02\/1738675182.jpg\" alt=\"Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges - More Stocks Inside\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges &ndash; More Stocks Inside<\/p>\n<p style=\"text-align: justify;\">As <strong>global defense spending surges<\/strong>, investors are turning their attention to <strong>AI-driven military technologies<\/strong>, fueling demand for <strong>secure, high-speed communication systems<\/strong>. <strong>Peraso Inc. (NASDAQ: PRSO)<\/strong> is emerging as a <strong>key player<\/strong> in this evolving sector, leveraging its <strong>millimeter wave (mmWave) technology<\/strong> to provide <strong>low-latency, interference-free communications<\/strong>, critical for <strong>military drone surveillance, real-time battlefield intelligence, and defense networking<\/strong>. With <strong>defense agencies prioritizing next-gen connectivity solutions<\/strong>, <strong>PRSO stands poised for potential military contracts and strategic partnerships<\/strong>. Also <strong>AI-powered biotech stocks<\/strong> gaining attention, mentioned inside this article.<\/p>\n<p style=\"text-align: justify;\"><strong>Financial &amp; Market Indicators:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Defense Spending Growth<\/strong>: The <strong>U.S. defense budget exceeded $850 billion in 2024<\/strong>, with <strong>AI-driven military projects<\/strong> receiving <strong>increased funding<\/strong> for <strong>advanced communication and security solutions<\/strong>&mdash;a sector where <strong>Peraso&rsquo;s mmWave technology thrives<\/strong>.<\/li>\n<li><strong>Comparison to GSI Technology (NASDAQ: GSIT)<\/strong>: GSIT, which specializes in <strong>AI-powered military computing<\/strong>, saw a <strong>43% surge<\/strong> after securing a <strong>U.S. Army contract<\/strong>, underscoring the <strong>market potential<\/strong> for <strong>similar small-cap stocks<\/strong> like <strong>PRSO<\/strong>.<\/li>\n<li><strong>Potential for Military Contracts<\/strong>: PRSO&rsquo;s <strong>mmWave solutions<\/strong> align with <strong>government and defense agency needs<\/strong>, making it a <strong>top contender for future defense technology contracts<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Why PRSO is a Smart Play for Defense Investors:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>High-Security Communication<\/strong>: <strong>PRSO&rsquo;s mmWave technology<\/strong> is <strong>resistant to jamming and interference<\/strong>, making it ideal for <strong>military drone operations<\/strong> and <strong>secure battlefield intelligence<\/strong>.<\/li>\n<li><strong>Growing Industry Momentum<\/strong>: As <strong>military AI adoption accelerates<\/strong>, investors are seeking <strong>defense-tech crossover stocks<\/strong>, positioning <strong>PRSO as a rare, publicly traded player in this space<\/strong>.<\/li>\n<li><strong>Small-Cap Growth Potential<\/strong>: <strong>Unlike large-cap defense stocks<\/strong>, PRSO remains <strong>undervalued<\/strong>, giving <strong>early investors<\/strong> a chance to <strong>capitalize on its emerging role<\/strong> in <strong>AI-powered defense technology<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Additional AI Medical Market Movers to Watch:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Kairos Pharma (NYSE: KAPA)<\/strong> is pioneering <strong>immune-suppression resistant cancer therapeutics<\/strong>, with a pipeline targeting <strong>prostate cancer, lung cancer, breast cancer, and glioblastoma<\/strong>.<\/li>\n<li><strong>Quantum BioPharma (NASDAQ: QNTM)<\/strong> confirmed its supplement <strong>unbuzzd&trade; accelerates alcohol metabolism<\/strong>, reducing <strong>BAC by over 40% in 30 minutes<\/strong>, improving <strong>alertness and cognitive function<\/strong>.<\/li>\n<li><strong>Evaxion Biotech (NASDAQ: EVAX)<\/strong> closed a <strong>$10.8 million public offering<\/strong> to advance its <strong>AI-powered cancer immunotherapy candidates<\/strong>, backed by <strong>Merck&rsquo;s MSD Global Health Innovation Fund<\/strong>.<\/li>\n<li><strong>Invivyd (NASDAQ: IVVD)<\/strong> reported <strong>positive Phase 1\/2 clinical data<\/strong> for <strong>VYD2311<\/strong>, a <strong>long-acting alternative to COVID-19 vaccines<\/strong>, with <strong>17x greater neutralization potency<\/strong> than pemivibart.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">As <strong>defense budgets rise<\/strong> and <strong>AI-driven military tech<\/strong> advances, <strong>PRSO&rsquo;s mmWave solutions<\/strong> present a <strong>strong investment opportunity<\/strong> in the <strong>defense-tech sector<\/strong>. Meanwhile, <strong>AI-powered biotech stocks like KAPA, QNTM, IVVD and EVAX, <\/strong>are gaining traction in <strong>next-gen immunotherapy and antibody treatments<\/strong>, highlighting <strong>AI&rsquo;s impact on healthcare<\/strong>. With <strong>potential military contracts and industry momentum<\/strong>, <strong>PRSO is poised for breakout growth<\/strong>, making it a <strong>top watchlist stock alongside KAPA, QNTM, IVVD, EVAX and GSIT.<\/strong><\/p>\n<p style=\"text-align: justify;\">Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions &amp; quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor&#8217;s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.&#8221;TSR&#8221; is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. &#8220;TSR&#8221; authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. &#8220;TSR&#8221; has not been compensated to produce content related to &#8220;Any Companies&#8221; appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/thestreetreports.com_113087.html\" rel=\"nofollow\">The Street Reports<\/a><br \/><strong>Contact Person:<\/strong> Editor<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=peraso-inc-nasdaq-prso-rides-military-ai-boom-as-defense-spending-surges-more-stocks-inside\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.thestreetreports.com\" target=\"_blank\" rel=\"nofollow\">http:\/\/www.thestreetreports.com<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=peraso-inc-nasdaq-prso-rides-military-ai-boom-as-defense-spending-surges-more-stocks-inside\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges &ndash; More Stocks Inside As global defense spending surges, investors are turning their attention to AI-driven military technologies, fueling demand for secure, high-speed communication systems. Peraso Inc. (NASDAQ: &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/peraso-inc-nasdaq-prso-rides-military-ai-boom-as-defense-spending-surges-more-stocks-inside_730116.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,427,406,411],"tags":[],"class_list":["post-730116","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Personal-Finance","category-Pharmaceuticals-Biotech","category-Technology"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/730116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=730116"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/730116\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=730116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=730116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=730116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}